Dendritic cell vaccine for recurrent high-grade gliomas in pediatric and adult subjects: Clinical trial protocol

Neurosurgery

Volumn 73, Issue 5, 2013, Pages 863-867

  Shah, Ashish H ^a   Bregy, Amade ^a   Heros, Deborah O ^a   Komotar, Ricardo J ^a   Goldberg, John ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

Clinical trial; Dendritic cell vaccine; Malignant gliomas

Indexed keywords

DENDRITIC CELL VACCINE;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER PREVENTION; CANCER RECURRENCE; CLINICAL ARTICLE; DRUG SAFETY; GLIOMA; HUMAN; IMMUNE RESPONSE; PREOPERATIVE PERIOD; PRIORITY JOURNAL; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; BRAIN NEOPLASMS; CANCER VACCINES; COHORT STUDIES; DENDRITIC CELLS; FEMALE; GLIOMA; HUMANS; IMMUNOTHERAPY; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84886593015     PISSN: 0148396X     EISSN: None     Source Type: Journal    
DOI: 10.1227/NEU.0000000000000107     Document Type: Article

References (19)

1. Frankel SA, German WJ. Glioblastoma multiforme; review of 219 cases with regard to natural history, pathology, diagnostic methods, and treatment. J Neurosurg. 1958;15(5):489-503
2. Kelly KA, Kirkwood JM, Kapp DS. Glioblastoma multiforme: Pathology, natural history and treatment. Cancer Treat Rev. 1984;11(1):1-26
3. Rock K, McArdle O, Forde P, et al. A clinical review of treatment outcomes in glioblastoma multiforme-the validation in a non-trial population of the results of a randomised Phase III clinical trial: Has a more radical approach improved survival? Br J Radiol. 2012;85(1017):e729-e733
4. Birol Sarica F, Tufan K, Cekinmez M, et al. Effectiveness of temozolomide treatment used at the same time with radiotherapy and adjuvant temozolomide; concomitant therapy of glioblastoma multiforme: Multivariate analysis and other prognostic factors. J Neurosurg Sci. 2010;54(1):7-19
5. Lai A, Kharbanda S, Pope WB, et al. Evidence for sequenced molecular evolution of IDH1 mutant glioblastoma from a distinct cell of origin. J Clin Oncol. 2011;29(34):4482-4490
6. Kim Y, Kim KH, Lee J, et al. Wnt activation is implicated in glioblastoma radioresistance. Lab Invest. 2011;92(3):466-473
7. Ardon H, Van Gool S, Lopes IS, et al. Integration of autologous dendritic cellbased immunotherapy in the primary treatment for patients with newly diagnosed glioblastoma multiforme: A pilot study. J Neurooncology. 2010;99(2):261-272
8. Ardon H, Van Gool SW, Verschuere T, et al. Integration of autologous dendritic cell-based immunotherapy in the standard of care treatment for patients with newly diagnosed glioblastoma: Results of the HGG-2006 phase I/II trial. Cancer Immunol Immunother. 2012;61(11):2033-2044
9. Chang CN, Huang YC, Yang DM, et al. A phase I/II clinical trial investigating the adverse and therapeutic effects of a postoperative autologous dendritic cell tumor vaccine in patients with malignant glioma. J Clin Neurosci Official J Neurosurg Soc Australasia. 2011;18(8):1048-1054
10. Cho DY, Yang WK, Lee HC, et al. Adjuvant immunotherapy with whole-cell lysate dendritic cells vaccine for glioblastoma multiforme: A phase II clinical trial. World Neurosurg. 2012;77(5-6):736-744
11. Liau LM, Prins RM, Kiertscher SM, et al. Dendritic cell vaccination in glioblastoma patients induces systemic and intracranial T-cell responses modulated by the local central nervous system tumor microenvironment. Clinical Cancer Research. 2005;11(15):5515-5525
12. Phuphanich S, Wheeler CJ, Rudnick JD, et al. Phase I trial of a multi-epitope-pulsed dendritic cell vaccine for patients with newly diagnosed glioblastoma. Cancer Immunol Immunother. 2013;62(1):125-135
13. Wheeler CJ, Black KL, Liu G, et al. Vaccination elicits correlated immune and clinical responses in glioblastoma multiforme patients. Cancer Res. 2008;68(14): 5955-5964
14. Yu JS, Wheeler CJ, Zeltzer PM, et al. Vaccination of malignant glioma patients with peptide-pulsed dendritic cells elicits systemic cytotoxicity and intracranial T-cell infiltration. Cancer Res. 2001;61(3):842-847
15. Nair S, McLaughlin C, Weizer A, et al. Injection of immature dendritic cells into adjuvant-treated skin obviates the need for ex vivo maturation. J Immunol. 2003; 171(11):6275-6282
16. Kikuchi T, Akasaki Y, Abe T, et al. Vaccination of glioma patients with fusions of dendritic and glioma cells and recombinant human interleukin 12. J Immunother. 2004;27(6):452-459
17. Kikuchi T, Akasaki Y, Irie M, Homma S, Abe T, Ohno T. Results of a phase I clinical trial of vaccination of glioma patients with fusions of dendritic and glioma cells. Cancer Immunol Immunother. 2001;50(7):337-344
18. Liau LM, Black KL, Martin NA, et al. Treatment of a patient by vaccination with autologous dendritic cells pulsed with allogeneic major histocompatibility complex class I-matched tumor peptides. Case Report. Neurosurg Focus. 2000;9(6):e8
19. Bregy A, Wong TM, Shah AH, Golberg JM, Komotar RJ. Active immunotherapy using dendritic cells in the treatment of glioblastoma multiforme. Cancer Treat Rev. 2013;39(8):891-907